Home Biosimilar Antibodies Others CD markers Tafasitamab (Anti-CD19)
For research use only. Not for use in humans.

Tafasitamab (Anti-CD19)

Synonyms: CD19,B4

Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD.

Tafasitamab (Anti-CD19)

2 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 10.3mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD.

Product Details

CAS No. 1422527-84-1
Molecular Weight 144.56 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03620058 ACTIVE_NOT_RECRUITING Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia University of Pennsylvania 2018-09-27 PHASE1
NCT07549698 RECRUITING Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia; Immune Thrombocytopenic Purpura CRISPR Therapeutics AG 2026-06 PHASE1; PHASE2
NCT06925542 RECRUITING SLE (Systemic Lupus); Lupus Erythematosus, Systemic; Lupus Nephritis; Systemic Sclerosis; Inflammatory Myopathy, Idiopathic; Myositis; Diffuse Cutaneous Systemic Sclerosis CRISPR Therapeutics 2025-03-10 PHASE1
NCT07126236 RECRUITING Drug: Epcoritamab|Drug: Epcoritamab, tafasitamab and lenalid Large B Cell Lymphoma Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2025-08-04 PHASE2
NCT07283679 RECRUITING Drug: ONC-PluReceptor NK cells Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma M.D. Anderson Cancer Center 2026-02-24 PHASE1; PHASE2
NCT07162571 NOT_YET_RECRUITING Acute Lymphobkastic Leukemia; B Cell Lymphoma Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 2026-01-01 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-10-14)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.